AICAR

AICAR is described as an AMPK agonist that chemically makes cells behave as if they are energy depleted, similar to signals produced by exercise or fasting. The protocol explains that after administration, AICAR enters cells (notably skeletal muscle) and is converted to ZMP (AICAR monophosphate), an AMP analog that directly activates AMPK. AMPK is presented as a master regulator of energy homeostasis; once activated, it increases glucose uptake and fatty-acid oxidation, promotes mitochondrial biogenesis, and shifts metabolism toward higher energy output and improved endurance capacity. The page highlights classic animal research in which sedentary mice given AICAR demonstrated substantial endurance increases without training, illustrating the ‘exercise mimetic’ concept. It also notes that human safety data exist mainly from IV acadesine studies (not routine use), with generally tolerable short-term effects at much higher per-kg doses than research SC protocols. However, the page emphasizes that AICAR remains experimental, is not FDA-approved for therapeutic use, and that long-term human risk/benefit is not established.